20 results on '"Cannella, L"'
Search Results
2. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
3. 98P Potential predictive biomarkers for response to immunotherapy in breast angiosarcoma
4. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study
5. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
6. 1202P Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
7. 1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
8. Preclinical evaluations of a novel formulation of PD-L1-targeted liposomal doxorubicin for the treatment of hepatocellular carcinoma
9. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up
10. P066 Familiar occurrence of myelodysplastic sydrome with del(5q)
11. P016 Revised WHO 2008 classification of patients with RCUD (refractory cytopenia with unilineage dysplasia)
12. P017 WPSS versus Simplified Myelodysplastic Syndrome Risk Score: which is the best tool for prediction of survival in myelodysplastic patients?
13. P001 Prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
14. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
15. O-26 G-CSF AND PLERIXAFOR AS NON-TOXIC AND EFFECTIVE FIRST-LINE MOBILIZING APPROACH IN PATIENTS WITH MULTIPLE MYELOMA CANDIDATE TO ASCT
16. 339 Deferasirox treatment in myelodysplastic syndromes: “Real-life” efficacy and safety in a single institution patient population
17. 289 Prognostic evaluation of chronic myelomonocytic leukemia (CMML) with different prognostic models
18. 142 Myelodysplastic syndrome patients younger than 50 years: Epidemiological data and clinical features
19. Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature
20. Irradiation influences endothelial cell function in vitro and in vivo: A possible role for IP10
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.